跳至主要内容
临床试验/ISRCTN67104246
ISRCTN67104246进行中(未招募)3 期

EASE: Evaluating Antidepressants for emotionaliSm after strokE: a multi-centre, randomised, double-blind, placebo-controlled trial to establish the effect(s) of administration of sertraline (50 mg once daily for 6 months) in people with a recent stroke and post-stroke emotionalism

orfolk and Norwich University Hospitals NHS Foundation Trust0 个研究点目标入组 310 人开始时间: 2024年8月2日最近更新:
适应症

试验速览

阶段
3 期
状态
进行中(未招募)
入组人数
310

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Age =18 years
  • 2. Clinical diagnosis of first or repeat acute stroke (all types) in past one year with imaging compatible with ischaemic or haemorrhagic stroke (including those with normal CT if clinical history strongly suggestive of stroke).
  • 3. Any PSE sub-type (crying, laughter, combined) defined by CNS-LS score =13
  • 4. Capacity, as assessed by the patient’s attending physician, to consent and complete trial assessments

排除标准

  • Current exclusion criteria as of 05/08/2024:
  • 1. Significant medical condition that in the opinion of the patient’s attending physician would affect subject safety or influence the study outcomes
  • 2. Allergy to sertraline
  • 3. Contraindication to sertraline - known hepatic impairment, known long QT syndrome, close angle glaucoma, history of chronic kidney disease (CKD) or chronic obstruction pulmonary disease (COPD), using a medication that could interact seriously with sertraline e.g. pimozide, monoamine oxidase inhibitors and other serotonergic drugs (amphetamines, triptans and fentanyl)
  • 4. Current or recent (within 1 month) treatment with any SSRI antidepressant or irreversible monoamine oxidase inhibitors (MAOIs)
  • 5. Recent (within 1 month) change in non-SSRI antidepressants. Those on a stable dose for 1 month or more will still be eligible, including those having psychological therapies for anxiety/depression
  • 6. Current or known history of hyponatraemia
  • 7. Enrolment in another CTIMP interventional study or not available for full follow-up duration
  • 8. A known history of a drug overdose, self-harm or attempted suicide in the last three months
  • 9. Pregnant or breastfeeding
  • 10. Women of childbearing potential (WOCBP) and not using a highly effective form of contraception (see section 6.3 for full definitions)
  • 11. Unable or prefers not to undertake trial assessments remotely. Options to participate will include by post, telephone or video calls or completion of assessments online
  • Previous exclusion criteria:
  • 1. Significant medical condition that in the opinion of the patient’s attending physician would affect subject safety or influence the study outcomes
  • 2. Allergy to sertraline
  • 3. Contraindication to sertraline - including known hepatic impairment, known long QT syndrome, close angle glaucoma, history of Chronic Kidney Disease (CKD) or Chronic Obstruction Pulmonary disease (COPD), using a medication that could interact seriously with sertraline e.g. pimozide, monoamine oxidase inhibitors and other serotonergic drugs (amphetamines, triptans and fentanyl)
  • 4. Current or recent (within 1 month) treatment with any SSRI antidepressant or irreversible monoamine oxidase inhibitors (MAOIs)
  • 5. Recent (within 1 month) change in non-SSRI antidepressants. Those on a stable dose for 1 month or more will still be eligible, including those having psychological therapies for anxiety/depression
  • 6. Enrolment in another CTIMP interventional study or not available for full follow-up duration
  • 7. A known history of a drug overdose, self-harm or attempted suicide in the last three months
  • 8. Pregnant, breastfeeding or of childbearing age and not using contraception
  • 9. Unable or prefers not to undertake trial assessments remotely. Options to participate will include by post, telephone or video calls or completion of assessments online

研究者

相似试验